QuantalX is developing DELPHITM, a simple, precise and objective evaluation of functional brain status to enable early prevention of brain degeneration. Modern medicine lacks the ability to successfully cope with brain disorders, yet 35% of all disease burden is attributed to brain disorders. DELPHI™ is the first patient‑independent active cerebral function imaging system that delivers a visual map of brain network health.
The fair value of the investment in QunatalX is minimal.

QuantalX - NetScientific